- Home
- EHAB vs AUTL Comparison
EHAB vs AUTL Comparison
Compare EHAB & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EHAB | AUTL |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.3M | 433.8M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | EHAB | AUTL |
|---|---|---|
| Price | $10.78 | $1.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $12.67 | $8.33 |
| AVG Volume (30 Days) | 368.2K | ★ 2.3M |
| Earning Date | 03-04-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,047,800,000.00 | $51,128,000.00 |
| Revenue This Year | $4.46 | $672.42 |
| Revenue Next Year | $4.16 | $84.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 1.02 | ★ 406.67 |
| 52 Week Low | $6.47 | $1.11 |
| 52 Week High | $11.35 | $2.70 |
Technical Indicators
Market Signals| Indicator | EHAB | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 60.74 | 40.82 |
| Support Level | $10.21 | $1.36 |
| Resistance Level | $11.35 | $1.48 |
| Average True Range (ATR) | 0.33 | 0.08 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 49.56 | 23.97 |
Price Performance
Historical ComparisonAbout EHAB Enhabit Inc.
Enhabit Inc provides home health and hospice services in the United States. Its reportable segments are Home Health and Hospice. The Home Health segment includes a comprehensive range of Medicare-certified home nursing services for adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The Hospice segment focuses on the quality of life for patients who are experiencing a life-limiting illness while treating the person and symptoms of the disease, rather than the disease itself. The company generates a majority of its revenue from the Home Health segment.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.